{
    "nct_id": "NCT03856658",
    "official_title": "A Phase II Trial of Hepatic Artery Infusional Floxuridine with Systemic Chemotherapy in the Treatment of Pancreatic Cancer Liver Metastases",
    "inclusion_criteria": "* Biopsy-proved pancreatic adenocarcinoma with synchronous liver metastases\n* Elevated Cancer Antigen 19-9 (CA19-9) at diagnosis (>37 U/mL)\n* Ages 18-75 years\n* Karnofsky performance status â‰¥70\n* Ability to undergo general anesthesia and HAI pump placement procedure\n* CT or MRI scan imaging of the abdomen demonstrating accessibility of the gastroduodenal artery within 2 months of enrollment\n* Received a minimum of 2 months of systemic chemotherapy with stable tumor markers and imaging.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 75 Years",
    "exclusion_criteria": "* Primary tumor resected\n* Model for End Stage Liver Disease (MELD) score >20, using the variables of: Bilirubin, serum Sodium, International Normalized Ratio (INR), serum Creatinine, and Dialysis twice in the past week.\n* Greater than 60% liver parenchymal involvement by tumor\n* Evidence of peritoneal metastases\n* Current alcohol abuse\n* Pregnant or lactating women",
    "miscellaneous_criteria": ""
}